← Leaderboards
Howard J. Federoff
University Of Rochester
$26,721,440
Attributed
$26,721,440
Total exposure
17
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8.4M · FY2005–12$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$47,330,112 · 20
By mechanism
R01$13,126,561 · 8
U54$9,837,215 · 2
M01$6,859,068 · 1
G20$4,671,189 · 1
P30$4,076,025 · 1
RC2$3,907,801 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- Joseph D. Rosenblatt$6,445,612
- John A Olschowka$2,892,339
- William J Bowers$3,529,197
- Thomas G Evans$1,031,011
Others in their field
Top investigators on “Gene Expression”
- Jeffrey P Krischer · University Of South Florida$137,481,663
- Eric S Lander · Whitehead Institute For Biomedical Res$128,154,716
- Stacey Gabriel · Massachusetts Institute Of Technology$86,302,566
- Bruce W Stillman · Cold Spring Harbor Laboratory$82,324,317
- Michael P Snyder · Yale University$75,701,723
- Ronald G Crystal · Weill Medical College Of Cornell Univ$74,774,977
Research focus
Gene ExpressionLaboratory MouseProteinsGenesNeuronsMolecularTransfection /Expression VectorMediatingAgingGenetically Modified AnimalsCessation Of LifeDopamineSynapsesIn VivoAffectAlzheimer&AposLifeNeurodegenerative DisordersBiologicalBrainIn VitroBiomedical FacilityResearch StudyGene Therapy
Grant awards (78)
Leukocyte-derived Biomarkers as Predictors of Risk and Progression in AD$573,745
R01 · FY2012 · AG · contact PI
Leukocyte-derived Biomarkers as Predictors of Risk and Progression in AD$589,733
R01 · FY2011 · AG · contact PI
HIF-1a Function in Astrocytes: Deciphering Pro-death and Pro-survival Roles$393,716
P01 · FY2011 · NS · contact PI
MECHANICAL SYSTEMS RENOVATION$4,671,189
G20 · FY2010 · RR · contact PI
A Novel Monkey Model for Parkinson's Drug Discovery$1,949,249
RC2 · FY2010 · NS · contact PI
Leukocyte-derived Biomarkers as Predictors of Risk and Progression in AD$614,097
R01 · FY2010 · AG · contact PI
Dopamine, mutant synuclein, oxidative stress and inflammation$452,081
R01 · FY2010 · NS · contact PI
HIF-1a Function in Astrocytes: Deciphering Pro-death and Pro-survival Roles$402,041
P01 · FY2010 · NS · contact PI
Nectin-1: Synaptic processing and functions$296,444
R01 · FY2010 · AG · contact PI
General Clinical Research Center$2,268,756
M01 · FY2009 · RR · contact PI
A Novel Monkey Model for Parkinson's Drug Discovery$1,958,552
RC2 · FY2009 · NS · contact PI
Leukocyte-derived Biomarkers as Predictors of Risk and Progression in AD$619,393
R01 · FY2009 · AG · contact PI
Dopamine, mutant synuclein, oxidative stress and inflammation$440,190
R01 · FY2009 · NS · contact PI
HIF-1a Function in Astrocytes: Deciphering Pro-death and Pro-survival Roles$403,569
P01 · FY2009 · NS · contact PI
Nectin-1: Synaptic processing and functions$299,439
R01 · FY2009 · AG · contact PI
General Clinical Research Center$2,268,756
M01 · FY2008 · RR · contact PI
Leukocyte-derived Biomarkers as Predictors of Risk and Progression in AD$635,857
R01 · FY2008 · AG · contact PI
HIF-1a Function in Astrocytes: Deciphering Pro-death and Pro-survival Roles$398,531
P01 · FY2008 · NS · contact PI
Nectin-1: Synaptic processing and functions$299,439
R01 · FY2008 · AG · contact PI
Peripheral Macrophage Signatures of Inflammation in Neurodegenerative Diseases$268,625
R21 · FY2008 · NS · contact PI
General Clinical Research Center$2,321,556
M01 · FY2007 · RR · contact PI
Nectin-1: Synaptic processing and functions$310,526
R01 · FY2007 · AG · contact PI
HIF-1a Function in Astrocytes: Deciphering Pro-death and Pro-survival Roles$307,367
P01 · FY2007 · NS · contact PI
Peripheral Macrophage Signatures of Inflammation in Neurodegenerative Diseases$100,734
R21 · FY2007 · NS · contact PI
Parkinson's Disease Gene Therapy Study Group$2,253,999
U54 · FY2006 · NS · contact PI
HSV Amplicon-mediated Disruption of Abeta Fibrillogenesis$372,962
R01 · FY2006 · AG · contact PI
Nectin-1: Synaptic processing and functions$319,800
R01 · FY2006 · AG · contact PI
Interdepartmental Neuroscience Training$199,220
T32 · FY2006 · NS · contact PI
Proteomic Biomarker Discovery in PD$112,011
R21 · FY2006 · NS · contact PI
Proteomic Biomarker Discovery in PD$64,125
R21 · FY2006 · NS · contact PI
Parkinson's Disease Gene Therapy Study Group$1,588,339
U54 · FY2005 · NS
Improved HSV Vectors: Gene Transfer into Nervous System$509,339
R01 · FY2005 · NS
HSV Amplicon-mediated Disruption of Abeta Fibrillogenesis$381,938
R01 · FY2005 · AG
Interdepartmental Neuroscience Training$291,351
T32 · FY2005 · NS
Proteomic Biomarker Discovery in PD$180,375
R21 · FY2005 · NS
Peripheral Leukocyte Biomarkers in Alzheimer's Disease$124,800
R21 · FY2005 · AG
Parkinson's Disease Gene Therapy Study Group$116,000
U54 · FY2005 · NS
HSV Amplicon-mediated Disruption of Abeta Fibrillogenesis$76,306
R01 · FY2005 · AG
Parkinson's Disease Gene Therapy Study Group$1,976,669
U54 · FY2004 · NS
ROCHESTER NATHAN SHOCK CENTER$797,593
P30 · FY2004 · AG
Improved HSV Vectors: Gene Transfer into Nervous System$491,021
R01 · FY2004 · NS
HSV Amplicon-mediated Disruption of Abeta Fibrillogenesis$381,938
R01 · FY2004 · AG
INTERDEPARTMENTAL NEUROSCIENCE TRAINING$259,498
T32 · FY2004 · NS
Peripheral Leukocyte Biomarkers in Alzheimer's Disease$218,400
R21 · FY2004 · AG
ROCHESTER NATHAN SHOCK CENTER$81,750
P30 · FY2004 · AG
Parkinson's Disease Gene Therapy Study Group$1,860,926
U54 · FY2003 · NS
ROCHESTER NATHAN SHOCK CENTER$774,363
P30 · FY2003 · AG
Improved HSV Vectors: Gene Transfer into Nervous System$473,235
R01 · FY2003 · NS
HSV Amplicon-mediated Disruption of Abeta Fibrillogenesis$381,938
R01 · FY2003 · AG
INTERDEPARTMENTAL NEUROSCIENCE TRAINING$254,288
T32 · FY2003 · NS
Single-chain Antibody Therapy for Prion Disease$157,500
R21 · FY2003 · AG
Parkinson's Disease Gene Therapy Study Group$77,646
U54 · FY2003 · NS
ROCHESTER NATHAN SHOCK CENTER$52,700
P30 · FY2003 · AG
Parkinson's Disease Gene Therapy Study Group$1,800,000
U54 · FY2002 · NS
ROCHESTER NATHAN SHOCK CENTER$751,813
P30 · FY2002 · AG
ENVIRONMENTAL NEUROTOXICANT GENETIC ACTION--MURINE MODEL$458,023
R01 · FY2002 · ES
Improved HSV Vectors: Gene Transfer into Nervous System$455,967
R01 · FY2002 · NS
METHODS FOR ANALYSIS OF GENE FUNCTION IN NEURAL NETWORKS$435,662
R01 · FY2002 · AG
INTERDEPARTMENTAL NEUROSCIENCE TRAINING$236,022
T32 · FY2002 · NS
Core--Biological measurement$163,636
U54 · FY2002 · NS
Single-chain Antibody Therapy for Prion Disease$157,500
R21 · FY2002 · AG
ROCHESTER NATHAN SHOCK CENTER$90,000
P30 · FY2002 · AG
ROCHESTER NATHAN SHOCK CENTER$72,923
P30 · FY2002 · AG
ROCHESTER NATHAN SHOCK CENTER$739,989
P30 · FY2001 · AG
Improved HSV Vectors: Gene Transfer into Nervous System$487,202
R01 · FY2001 · NS
ENVIRONMENTAL NEUROTOXICANT GENETIC ACTION--MURINE MODEL$444,683
R01 · FY2001 · ES
METHODS FOR ANALYSIS OF GENE FUNCTION IN NEURAL NETWORKS$422,973
R01 · FY2001 · AG
SOMATIC MOSAIC ANALYSIS OF NGF FUNCTION IN MICE$288,801
R01 · FY2001 · MH
INTERDEPARTMENTAL NEUROSCIENCE TRAINING$216,868
T32 · FY2001 · NS
METHODS FOR ANALYSIS OF GENE FUNCTION IN NEURAL NETWORKS$95,589
R01 · FY2001 · AG
IMPROVED HSV VECTORS--GENE TRANSFER INTO NEROUS SYSTEM$79,750
R01 · FY2001 · NS
ROCHESTER NATHAN SHOCK CENTER$64,893
P30 · FY2001 · AG
ROCHESTER NATHAN SHOCK CENTER$650,001
P30 · FY2000 · AG
ENVIRONMENTAL NEUROTOXICANT GENETIC ACTION--MURINE MODEL$461,731
R01 · FY2000 · ES
METHODS FOR ANALYSIS OF GENE FUNCTION IN NEURAL NETWORKS$427,954
R01 · FY2000 · AG
SOMATIC MOSAIC ANALYSIS OF NGF FUNCTION IN MICE$280,389
R01 · FY2000 · MH
IMPROVED HSV VECTORS--GENE TRANSFER INTO NEROUS SYSTEM$268,416
R01 · FY2000 · NS
INTERDEPARTMENTAL NEUROSCIENCE TRAINING$105,712
T32 · FY2000 · NS